Amelioration of hepatorenal syndrome with selective endothelin-A antagonist

被引:64
作者
Soper, CPR [1 ]
Latif, AB [1 ]
Bending, MR [1 ]
机构
[1] ST GEORGE HOSP,SCH MED,LONDON,ENGLAND
关键词
D O I
10.1016/S0140-6736(96)91667-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:1842 / 1843
页数:2
相关论文
共 5 条
[1]  
HECKER R, 1956, LANCET, V2, P1121
[2]  
IWATSUKI S, 1973, New England Journal of Medicine, V289, P1155, DOI 10.1056/NEJM197311292892201
[3]   PATHOGENESIS AND MANAGEMENT OF THE HEPATORENAL-SYNDROME [J].
LAFFI, G ;
LAVILLA, G ;
GENTILINI, P .
SEMINARS IN LIVER DISEASE, 1994, 14 (01) :71-81
[4]   PLASMA ENDOTHELIN IMMUNOREACTIVITY IN LIVER-DISEASE AND THE HEPATORENAL-SYNDROME [J].
MOORE, K ;
WENDON, J ;
FRAZER, M ;
KARANI, J ;
WILLIAMS, R ;
BADR, K .
NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (25) :1774-1778
[5]   EFFECTS OF ENDOTHELIN-1 ON RENAL-FUNCTION IN HUMANS - IMPLICATIONS FOR PHYSIOLOGY AND PATHOPHYSIOLOGY [J].
RABELINK, TJ ;
KAASJAGER, KAH ;
BOER, P ;
STROES, EG ;
BRAAM, B ;
KOOMANS, HA .
KIDNEY INTERNATIONAL, 1994, 46 (02) :376-381